Representative publications

Evidence-based healthcare

Obeng-Kusi M, et al. Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves. Expert Review of Pharmacoeconomics and Outcomes Research 2024, in press.

Abraham I, et al. On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: current status. Cancer Treatment and Research Communications 2024;40:100824.

Obeng-Kusi M, et al. The economic burden of ebola virus disease: a review and recommendations for analysis. Journal of Medical Economics 2024;27:309-323.

Abraham I, et al. Should a systematic review be required in a clinical trial report? Perhaps, but not yet. JAMA Network Open 2023;6:e234226.

Lewandrowski KU, et al. Differential agnostic effect size analysis of lumbar stenosis surgeries. International Journal of Spine Surgery 2022;16:318-342.

Lewandrowski KU, et al. A differential clinical benefit examination of full lumbar endoscopy vs interspinous process spacers in the treatment of spinal stenosis: an effect size meta-analysis of clinical outcomes. International Journal of Spine Surgery 2022;16:102-123. 

Alrawashdh N, et al. Comparative efficacy of first-line treatments of chronic lymphocytic leukemia: network meta-analyses of survival curves. Clinical Lymphoma, Myeloma, and Leukemia 2021;21:e820-e838.

Alhifany A, et al. Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis. Supportive Care in Cancer 2020:28:1031-1039.

Alkhushaym N, et al. Exposure to proton pump inhibitors and risk of pancreatic cancer: meta-analysis. Expert Opinion on Drug Safety 2020;19:327-334.

Almutairi AR, et al. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Frontiers in Oncology 2020;10:91.

Alhifany A, et al. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials. BMJ Open 2019;9:e031145.

Almutairi AR, et al. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: a Bayesian network meta-analysis. Critical Reviews in Oncology and Hematology 2019;142:16-25.

Oh M, et al. The association of BRCA1 and BRCA2 mutations and prostate cancer risk, frequency, and mortality: systematic review and meta-analysis. The Prostate 2019;79:880-895.

MacDonald KM, et al. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Review of Clinical Immunology 2019;15:553-569.

Tharp MD, et al. Benefits and harms of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a meta-analysis of “real-world” evidence. JAMA Dermatology 2019;155:29-38.

Al Yami MS, et al. Direct oral anticoagulants for the treatment of venous thromboembolism in patients with active malignancy: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis 2019;47:145-153, 166.

Oh YM, et al. BRCA1 and BRCA2 gene mutations and colorectal cancer risk: systematic review and meta-analysis. Journal of the National Cancer Institute 2018;110:1178-1189.

Bernstein JA, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of “real-world” evidence. Expert Opinion on Biological Therapy 2018;18:425-448.

Alhossan A, et al. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. Journal of Allergy and Clinical Immunology: In Practice 2017;5:1362-1370.

Finnane A, et al. on behalf of the International Society of Digital Imaging of the Skin (ISDIS) – International Skin Imaging Collaboration (ISIC).  Proposed technical guidelines in the acquisition of clinical images for documentation of skin related conditions. JAMA Dermatology 2017;153:453-457.

Katragadda C, et al. on behalf of the International Society of Digital Imaging of the Skin (ISDIS) –International Skin Imaging Collaboration (ISIC). Technique standards for skin lesion imaging: a Delphi consensus statement. JAMA Dermatology 2017;153:207-213.

Abraham I, et al. Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: review and pooled analysis of observational studies. Leukemia Research 2017;57:104-108.

Bokemeyer C, et al. Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study. Supportive Care in Cancer 2017;25:1819-1828.

Yun S, et al. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clinical Lymphoma Myeloma and Leukemia 2017;17:31-37.

Abraham I, et al. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy 2016;71:593-610.

Disclosure: The publications listed here blend articles reporting on studies and projects contracted to MATRIX45 and predecessor companies, independent projects initiated by MATRIX45, as well as academic projects by Ivo Abraham’s academic research groups.